Concord Biotech Ltd

Analyst / Investor Meet - Intimation

We would like to inform you that the officials of the Company will be attending an Investor Conference on 26th August 2026 as per the schedule and details in the file uploaded herewith.

Company Update / Analyst / Investor Meet View filing →

Analyst / Investor Meet - Outcome

The audio recording of the conference held on August 03, 2026 has been hosted on the website of the company and link to access the said recording is as follows: - Link : https://concordbiotech.com/wp-content/uploads/2026/08/Concord-Biotech-Q1-FY27-Earnings-Call-Audio-Recording.mp3 ....

Company Update / Analyst / Investor Meet View filing →

Shareholder Meeting / Postal Ballot-Outcome of AGM

The 41st Annual General Meeting Meeting of the Members of the Company was held on Friday July, 31, 2026 at 12:00 Noon through VC/OAVM. The summary of the proceedings are published herewith.

AGM/EGM / AGM View filing →

Board Meeting Intimation for Meeting To Be Held On Friday, July 31, 2026

Concord Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the unaudited Standalone and ....

Board Meeting / Board Meeting View filing →

Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended from time to time, read with Para A of Schedule III thereto, We wish to inform you that the Company has arranged ....

Company Update / Analyst / Investor Meet View filing →

Newspaper Publication

Newspaper Advertisement for Notice of 41st Annual General Meeting, Book Closure and Remove e-voting information

Company Update / Newspaper Publication View filing →

Notice Of 41St Annual General Meeting Of The Company For The Financial Year 2025-26

The Notice of 41st Annual General Meeting of the Company of scheduled to be held on Friday, July 31, 2026 through Video Conferencing (VC) / Other Audio-visual means(OAVM) at 12:00 Noon ....

AGM/EGM / AGM View filing →

Reg. 34 (1) Annual Report.

Annual Report for the financial year 2025-26

Others / Reg. 34 (1) Annual Report View filing →

Business Responsibility and Sustainability Reporting (BRSR)

Business Responsibility and Sustainability Report for financial year 2025-26

Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →

Intimation Of Record Date And Book Closure Date

The register of members and share transfer book of the Company will be closed from Saturday, July 25, 2026 to Friday, July 31, 2026. Further the Company has fixed Friday, July 24, 2026 ....

Corp. Action / Record Date View filing →

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate dated July 01, 2026 issued by MUFG Intime India Private Limited ....

Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

Newspaper Publication

Newspaper advertisement for Notice of 41st Annual General Meeting.

Company Update / Newspaper Publication View filing →

Completion Of Inspection By The Pharmacy And Poisons Board (PPB) From Kenya And The National Drug Authority (NDA) From Uganda At Unit-II Formulation Facility

We are pleased to announce the successful completion of inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit - II formulation ....

Company Update / General View filing →

Analyst / Investor Meet - Intimation

Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, scheduled to be held on 24th & 25th June, 2026.

Company Update / Analyst / Investor Meet View filing →

Completion Of ANVISA Inspection Conducted By The Brazilian Health Regulatory Agency At The Limbasi API Manufacturing Facility

We are pleased to announce the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at our API manufacturing facility in Limbasi. The inspection ....

Company Update / General View filing →

Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Tofacitinib Tablets, 5 Mg And 10 Mg

We are pleased to inform that the Company has received approval from USFDA for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg.

Company Update / General View filing →